Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CEO Sells 11,227 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 11,227 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $26.47, for a total value of $297,178.69. Following the transaction, the chief executive officer directly owned 38,773 shares in the company, valued at $1,026,321.31. The trade was a 22.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Maze Therapeutics Stock Performance

Maze Therapeutics stock traded up $0.34 during mid-day trading on Friday, hitting $26.21. 273,266 shares of the company’s stock traded hands, compared to its average volume of 637,671. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The firm has a 50 day simple moving average of $28.74 and a two-hundred day simple moving average of $31.20. Maze Therapeutics, Inc. has a fifty-two week low of $14.27 and a fifty-two week high of $53.65. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of -10.40 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.76). On average, research analysts expect that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on MAZE. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. BTIG Research reiterated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Finally, TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Maze Therapeutics has an average rating of “Buy” and an average target price of $66.00.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Royal Bank of Canada lifted its position in Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares during the period. Ameritas Investment Partners Inc. raised its position in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares in the last quarter. California State Teachers Retirement System raised its position in shares of Maze Therapeutics by 138.0% in the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after buying an additional 766 shares in the last quarter. Police & Firemen s Retirement System of New Jersey lifted its holdings in shares of Maze Therapeutics by 18.5% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock worth $247,000 after acquiring an additional 931 shares during the period. Finally, Legal & General Group Plc lifted its holdings in shares of Maze Therapeutics by 23.0% during the 3rd quarter. Legal & General Group Plc now owns 5,219 shares of the company’s stock worth $135,000 after acquiring an additional 977 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.